Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.54 |
| ▸ | FLT1 | P17948 | 12/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.54 |
| ▸ | FLT4 | P35916 | 7/20 | 0.42 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477341 | 0.85 | KDR (0.61) | KDRFLT1FGFR1FLT4EGFR | |
| SCHEMBL7736062 | 0.83 | KDR (0.69) | KDRFLT1FGFR1FLT4EGFR | |
| SCHEMBL6487092 | 0.81 | KDR (0.51) | KDRFLT1FGFR1FLT4EGFR | |
| SCHEMBL6519244 | 0.81 | KDR (0.59) | KDRFLT1FGFR1FLT4EGFR | |
| SCHEMBL6486350 | 0.81 | USP2 (0.50) | KDRFLT1FGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL6896039 | 0.80 | KDR (0.55) | KDRFLT1FGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL6485313 | 0.79 | KDR (0.51) | KDRFLT1FGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL6517812 | 0.78 | KDR (0.54) | KDRFLT1FGFR1FLT4EGFR | |
| SCHEMBL1890472 | 0.78 | KDR (0.62) | KDRFLT1FGFR1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL7460941 | 0.77 | KDR (0.52) | KDRFLT1FGFR1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA PHARMA S.A. (FR) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | NR5A1, NR5A2, CNKSR1 | KDR 13/4885FLT1 8/4885FGFR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.